Clinical Trial

Daratumumab Versus Rituximab in the Management of Pediatric Primary Immune Thrombocytopenia (ITP)

Name: Daratumumab Versus Rituximab in the Management of Pediatric Primary Immune Thrombocytopenia (ITP) — clinical trial record (NCT07362238)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Recruiting Phase 2

View on ClinicalTrials.gov →

Summary

This randomized, open-label study aim to compare the efficacy and safety of Daratumumab (anti-CD38 monoclonal antibody) with Rituximab in pediatric ITP patients.This study will be conducted in pediatric ITP patients who had not responded to or had relapsed after previous glucocorticoid treatment.

Trial Details

NCT Number	NCT07362238
Lead Sponsor	Institute of Hematology & Blood Diseases Hospital, China
Conditions	Immune Thrombocytopenia, Treatment
Enrollment	122 participants
Start Date	2026-03
Primary Completion	2028-03 (estimated)
Study Completion	2028-03 (estimated)
Updated on ClinicalTrials.gov	2026-01-23